

DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, April 7, 2026 – Diasorin S.p.A. ("Diasorin" or the "Company") announces that, meeting the conditions set forth in Article 9-bis, paragraph 3, of the Articles of Association, 32,092,668 ordinary shares of the Company - already increased pursuant to Article 9-bis, paragraph 2, of the Articles of Association - have accrued an additional incremental vote for a total of three votes for each share.

Pursuant to art. 85-bis, paragraph 4-bis, of Consob Regulation no. 11971/1999, the Company communicates the total amount of voting rights, with an indication of the number of shares that make up the capital:

	Updated situation			Previous situation		
	No. of shares that make up the share capital	No. of voting rights	Euro	No. of shares that make up the share capital	No. of voting rights	Euro
Total, of which:	55,948,257	120,133,843	55,948,257	55,948,257	88,041,075	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular enjoyment 01.01.2026) Current coupon: n. 21	23,855,339	23,855,339	-	23,855,439	23,855,439	-
Increased voting rights common shares – two votes per share ISIN IT0003492391 (regular enjoyment 01.01.2026) Current coupon: n. 21	250	500	-	32,092,818	64,185,636	-
Ordinary shares with increased voting rights – three votes per share ISIN IT0005188385 (regular enjoyment 01.01.2026) Current coupon: n. 21	32,092,668	96,278,004	-	-	-	-

The updated Special List, pursuant to Article 9-quarter, paragraph 3, of the Articles of Association, is available on the Company's website <https://int.diasorin.com/>, in the section "Group/Governance/Ownership Structure/Loyalty Shares".

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com